Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19487245 | 0.87 | LMNA (0.77) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL18239988 | 0.83 | PDE7A (1.00) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL9671609 | 0.82 | PDE7A (1.00) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL14010913 | 0.81 | TGM2 (0.75) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL18239991 | 0.79 | PDE7A (1.00) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL15864324 | 0.79 | NPC1 (0.59) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL9972171 | 0.79 | LMNA (0.74) | PDE7AALDH1A1SMN1; SMN2PDE7BTSHR | |
| SCHEMBL1101917 | 0.77 | LMNA (0.72) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL1101909 | 0.77 | LMNA (0.72) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B | |
| SCHEMBL9671522 | 0.77 | PDE7A (1.00) | PDE7AALDH1A1PTGS2SMN1; SMN2PDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | 4 SC AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-9951050-B2 | Method of inhibiting DYRK1B | 4 SC AG (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | 4SC DISCOVERY GMBH (DE) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633369-B2 | Method of inhibiting DYRK1B | SMO, GLI1, GRK2 | PDE7A 501/4885ALDH1A1 3401/4885PTGS2 1825/4885 |
| US-20180201606-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | PDE7A 501/4885ALDH1A1 3401/4885PTGS2 1825/4885 |
| US-20140371251-A1 | METHOD OF INHIBITING DYRK1B | SMO, GLI1, GRK2 | PDE7A 501/4885ALDH1A1 3401/4885PTGS2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.